Engineered control of the CAR-T-tumor synapse using customized DNA linkers 

Generation and characterization of fully human anti-CD19 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

Novel design and combinatory therapy to enhance chimeric antigen receptor engineered T cells (CAR-T) efficacy against solid tumor 

Engineering chimeric antigen receptor (CAR) -modified T cells for enhanced cancer immunotherapy 

Self-secretion of checkpoint blockade enhances antitumor immunity by murine chimeric antigen receptor-engineered T cells 

Improving antitumor efficacy of chimeric antigen receptor-engineered immune cell therapy with synthetic biology and combination therapy approaches 

Enhancing the specificity and cytotoxicity of chimeric antigen receptor Natural Killer cells 

Engineered CAR-T cells for treatment of solid cancers 

Enhancing the anti-cancer specificity of chimeric antigen receptor T cells through targeting HLA loss 

Lym-1 epitope targeted chimeric antigen receptor (CAR) T cells for the immunotherapy of cancer 

Phospho-proteomic analysis of immune cell activation 

Therapeutic resistance in acute lymphoblastic leukemia: cIAP2 inhibition sensitizes B cell acute lymphoblastic leukemia to anti-CD19 chimeric antigen receptor T cell 

Generation and characterization of humanized anti-CD19 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

Development of an NFAT-GFP Jurkat T cell reporter system for acceleration of T Cell receptor affinity screening 

Mechanistic model of chimeric antigen receptor T cell activation 

Engineering therapeutics for the improved antitumor efficacy of chimeric antigen receptor T cell therapy 

Generation and characterization of anti-CD138 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

Engineering chimeric antigen receptor-directed immune cells for enhanced antitumor efficacy in solid tumors 

The role of CD99 in T cells 

Immunotherapy of cancer 

Developing a bioluminescence tracking system targeting on tumor cells and T cells for cancer immunotherapy 

Tri-specific T cell engager immunotherapy targeting tumor initiating cells 

The immunomodulatory effects of midostaurin on T cells 

Tri-specific T cell engager immunotherapy targeting tumor initiating cells 

Investigating the effects of T cell mediated anti-leukemia activity in FLT3-ITD positive acute myeloid leukemia